Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study
Oncology and Therapy · 2024-09 · 12 (3) · 477-490
DOI: 10.1007/s40487-024-00289-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology and Therapy, online erschienen am 07.07.2024. Verfasst von Christian Schwabe und 4 weiteren Autor:innen. Beteiligte Einrichtung: New Zealand Clinical Research, Auckland, New Zealand. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
INTRODUCTION: This study evaluated the pharmacokinetic (PK) equivalence between BP02 (a proposed trastuzumab biosimilar) and the reference trastuzumab approved in the EU (EU-trastuzumab) and the US (US-trastuzumab). METHODS: In this phase 1, double-blind, parallel-group trial, 111 healthy male volunteers were randomized 1:1:1 to receive a single 6-mg/kg intravenous infusion of BP02, EU-trastuzumab, or US-trastuzumab and were evaluated for 78 days. Serum drug concentration-time data were analyzed by non-compartmental methods. The PK similarity of BP02 to the two reference products, and between EU-trastuzumab and US-trastuzumab, was determined using the standard 80-125% bioequivalence criteria. RESULTS: Baseline demographics for the 111 subjects with evaluable pharmacokinetics were similar across all treatment groups. PK profiles were similar for the three products. The 90% confidence intervals (CIs) for the ratios of area under the serum concentration-time curve (AUC) from the time of dosing to infinity (AUC0-inf), AUC from the time of dosing until the time of the last quantifiable concentration (AUC0-t), and peak serum concentration of trastuzumab (Cmax) were within 80% to 125% for all three pairwise comparisons. Adverse events (AEs) were similar across all arms, with treatment-related AEs reported by 73.0%, 73.0%, and 89.2% of the subjects in the BP02, EU-trastuzumab, and US-trastuzumab groups, respectively. The most common AEs were headache, infusion-related reactions, and upper-respiratory-tract infections. Four subjects-three in the US-trastuzumab group and one in the BP02 group-discontinued the study due to AEs. All post-dose samples except for two tested negative for anti-drug antibodies. CONCLUSION: This study demonstrates the PK similarity among BP02, EU-trastuzumab, and US-trastuzumab. The safety and immunogenicity profiles observed for the three products in this study are consistent with previous reports for trastuzumab. TRIAL REGISTRATION: ANZCTR number: ACTRN12621000573853.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- New Zealand Clinical Research, Auckland, New Zealand.
- CuraTeQ Biologics Private Limited, Unit XVII, Sy. No. 77 & 78, Indrakaran (v), Sangareddy Dist, Hyderabad, 502329, India.
- CuraTeQ Biologics Private Limited, Unit XVII, Sy. No. 77 & 78, Indrakaran (v), Sangareddy Dist, Hyderabad, 502329, India. Arpitkumar.Prajapati@curateqbio.com.
Zitieren
APA
Schwabe, C., Wynne, C., Dyapa, D. R., Prajapati, A., & Dadke, D. (2024). Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study. Oncology and Therapy, 12(3), 477-490. https://doi.org/10.1007/s40487-024-00289-0
Vancouver
Schwabe C, Wynne C, Dyapa DR, Prajapati A, Dadke D. Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study. Oncology and Therapy. 2024;12(3):477-490. doi:10.1007/s40487-024-00289-0
BibTeX
@article{Schwabe2024,
author = {Schwabe, Christian and Wynne, Chris and Dyapa, Dayaker Reddy and Prajapati, Arpitkumar and Dadke, Disha},
title = {Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study},
journal = {Oncology and Therapy},
year = {2024},
volume = {12},
number = {3},
pages = {477--490},
doi = {10.1007/s40487-024-00289-0}
}
EUVIMED